1956
DOI: 10.1016/0002-9343(56)90056-0
|View full text |Cite
|
Sign up to set email alerts
|

Oral phenylbutazone in the treatment of acute gouty arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
1
0

Year Published

1956
1956
1977
1977

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(2 citation statements)
references
References 11 publications
1
1
0
Order By: Relevance
“…Both these variables tended to be positively correlated with duration of attack after starting treatment and may therefore have introduced a bias against naproxen. Nevertheless, the preEent study shows that naproxen is equally as effective as phenylbutazone in the treatment of acute gout, the success rate (87 % phenylbutazone, 83 % naproxen) being similar to that previously reported for phenylbutazone (Boardman and Hart, 1965;Wilson et al, 1956).…”
Section: Discussionsupporting
confidence: 82%
“…Both these variables tended to be positively correlated with duration of attack after starting treatment and may therefore have introduced a bias against naproxen. Nevertheless, the preEent study shows that naproxen is equally as effective as phenylbutazone in the treatment of acute gout, the success rate (87 % phenylbutazone, 83 % naproxen) being similar to that previously reported for phenylbutazone (Boardman and Hart, 1965;Wilson et al, 1956).…”
Section: Discussionsupporting
confidence: 82%
“…However, in some cases the uricosuric effect is inadequate in the smaller doses, while larger doses may not be well tolerated, and in such circumstances the patient may experience little or no improvement. Phenylbutazone has been shown to have a good uricosuric effect when administered in doses of 0-6 to 1 g. daily (YU and others, 1953;Bishop and Beecher, 1953;Wyngaarden, 1955), and is also very effective in controlling the acute attacks of gouty arthritis (Kuzell, Schaffarzick, Naugler, Koets, Mankle, Brown, and Champlin, 1955;Wilson, Huffman, and Smyth, 1956). However, its salt retaining properties (Yu and others, 1953;Brodie, Lowman, Bums, and five others, 1954a) and reported toxicity (Kuzell, Schaffarzick, Naugler, Gaudin, Mankle, and Brown, 1954;Kuzell and others, 1955;Mauer, 1955) are a distinct disadvantage and have discouraged to a large extent its use for the treatment of chronic gout (Yu and others, 1953).…”
mentioning
confidence: 99%